Concepts (238)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epidermolysis Bullosa Dystrophica | 7 | 2025 | 14 | 2.450 |
Why?
|
| Epidermolysis Bullosa | 9 | 2024 | 12 | 2.150 |
Why?
|
| Skin Neoplasms | 10 | 2025 | 411 | 1.650 |
Why?
|
| Timolol | 2 | 2018 | 3 | 1.110 |
Why?
|
| Lasers, Dye | 2 | 2022 | 6 | 1.090 |
Why?
|
| Epidermolysis Bullosa, Junctional | 2 | 2023 | 2 | 0.980 |
Why?
|
| Infant | 18 | 2025 | 1718 | 0.910 |
Why?
|
| Facial Dermatoses | 2 | 2017 | 9 | 0.900 |
Why?
|
| Epidermolysis Bullosa Simplex | 3 | 2021 | 5 | 0.900 |
Why?
|
| Skin | 5 | 2022 | 436 | 0.790 |
Why?
|
| Ultraviolet Therapy | 1 | 2023 | 12 | 0.770 |
Why?
|
| Folliculitis | 2 | 2017 | 5 | 0.760 |
Why?
|
| Malassezia | 2 | 2017 | 5 | 0.750 |
Why?
|
| Hypopigmentation | 1 | 2023 | 15 | 0.750 |
Why?
|
| Child | 22 | 2025 | 4653 | 0.740 |
Why?
|
| Soft Tissue Injuries | 1 | 2022 | 20 | 0.730 |
Why?
|
| Humans | 55 | 2025 | 65845 | 0.670 |
Why?
|
| Hemangioma | 2 | 2018 | 27 | 0.670 |
Why?
|
| Conjunctivitis | 1 | 2020 | 5 | 0.660 |
Why?
|
| Tongue Diseases | 1 | 2020 | 5 | 0.660 |
Why?
|
| Skin Abnormalities | 1 | 2020 | 8 | 0.660 |
Why?
|
| Pilomatrixoma | 1 | 2020 | 3 | 0.650 |
Why?
|
| Hair Diseases | 1 | 2020 | 7 | 0.650 |
Why?
|
| Neonatal Abstinence Syndrome | 1 | 2021 | 43 | 0.650 |
Why?
|
| Acne Vulgaris | 3 | 2017 | 24 | 0.650 |
Why?
|
| Vitiligo | 1 | 2023 | 120 | 0.650 |
Why?
|
| Diaper Rash | 2 | 2014 | 3 | 0.650 |
Why?
|
| Petrolatum | 1 | 2020 | 1 | 0.640 |
Why?
|
| Exanthema | 1 | 2020 | 29 | 0.640 |
Why?
|
| Collagen Type VII | 3 | 2025 | 4 | 0.640 |
Why?
|
| Nail Diseases | 1 | 2021 | 51 | 0.630 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2018 | 152 | 0.630 |
Why?
|
| Dermatologic Agents | 2 | 2025 | 24 | 0.630 |
Why?
|
| Xanthomatosis | 1 | 2019 | 8 | 0.610 |
Why?
|
| Nevus, Pigmented | 3 | 2024 | 20 | 0.580 |
Why?
|
| Hemangioma, Capillary | 1 | 2018 | 4 | 0.570 |
Why?
|
| Drug Dosage Calculations | 1 | 2018 | 9 | 0.540 |
Why?
|
| Pigmentation Disorders | 2 | 2023 | 9 | 0.530 |
Why?
|
| Fractures, Multiple | 1 | 2017 | 2 | 0.510 |
Why?
|
| Menkes Kinky Hair Syndrome | 1 | 2017 | 3 | 0.510 |
Why?
|
| Administration, Topical | 5 | 2020 | 51 | 0.510 |
Why?
|
| Patient Care | 1 | 2017 | 79 | 0.500 |
Why?
|
| Skin Diseases | 3 | 2025 | 82 | 0.490 |
Why?
|
| Pregnancy Complications | 1 | 2021 | 389 | 0.490 |
Why?
|
| Dermatomycoses | 2 | 2008 | 18 | 0.480 |
Why?
|
| Male | 29 | 2025 | 31410 | 0.470 |
Why?
|
| Child Abuse | 1 | 2017 | 89 | 0.470 |
Why?
|
| Infant, Newborn | 8 | 2024 | 1439 | 0.460 |
Why?
|
| Keratin-14 | 2 | 2012 | 3 | 0.440 |
Why?
|
| Infant, Premature | 1 | 2017 | 199 | 0.430 |
Why?
|
| Adolescent | 14 | 2025 | 6368 | 0.420 |
Why?
|
| Diapers, Infant | 1 | 2014 | 2 | 0.420 |
Why?
|
| Sinus Pericranii | 1 | 2014 | 4 | 0.420 |
Why?
|
| Amniotic Band Syndrome | 1 | 2014 | 4 | 0.410 |
Why?
|
| Scalp | 1 | 2014 | 30 | 0.410 |
Why?
|
| Veins | 1 | 2014 | 63 | 0.400 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 532 | 0.400 |
Why?
|
| Nevus | 2 | 2025 | 23 | 0.400 |
Why?
|
| Hair | 1 | 2014 | 81 | 0.390 |
Why?
|
| Wound Healing | 2 | 2025 | 193 | 0.390 |
Why?
|
| Melanosis | 2 | 2023 | 10 | 0.380 |
Why?
|
| Loose Anagen Hair Syndrome | 1 | 2012 | 2 | 0.380 |
Why?
|
| Lichen Nitidus | 1 | 2012 | 2 | 0.370 |
Why?
|
| Psoriasis | 2 | 2025 | 59 | 0.370 |
Why?
|
| Aminoquinolines | 1 | 2012 | 16 | 0.370 |
Why?
|
| Diagnosis, Differential | 6 | 2019 | 993 | 0.370 |
Why?
|
| Lichen Planus | 1 | 2012 | 9 | 0.370 |
Why?
|
| Granuloma | 1 | 2012 | 43 | 0.360 |
Why?
|
| Child, Preschool | 10 | 2025 | 2090 | 0.360 |
Why?
|
| Retrospective Studies | 12 | 2023 | 6957 | 0.360 |
Why?
|
| Port-Wine Stain | 1 | 2011 | 10 | 0.350 |
Why?
|
| Dermatitis, Allergic Contact | 2 | 2015 | 9 | 0.340 |
Why?
|
| Female | 25 | 2025 | 34425 | 0.340 |
Why?
|
| Laser Therapy | 1 | 2011 | 41 | 0.340 |
Why?
|
| Allergens | 2 | 2015 | 54 | 0.340 |
Why?
|
| Adjuvants, Immunologic | 1 | 2012 | 238 | 0.330 |
Why?
|
| Dacryocystitis | 1 | 2009 | 2 | 0.310 |
Why?
|
| Neurofibromatosis 1 | 2 | 2023 | 30 | 0.300 |
Why?
|
| Fusarium | 1 | 2008 | 9 | 0.270 |
Why?
|
| Opportunistic Infections | 1 | 2008 | 29 | 0.270 |
Why?
|
| Dermatology | 3 | 2024 | 67 | 0.260 |
Why?
|
| Treatment Outcome | 5 | 2025 | 5834 | 0.250 |
Why?
|
| Giant Cell Tumors | 1 | 2025 | 8 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2024 | 2324 | 0.230 |
Why?
|
| Ustekinumab | 1 | 2025 | 4 | 0.230 |
Why?
|
| Pulmonary Eosinophilia | 1 | 2025 | 12 | 0.230 |
Why?
|
| Bronchitis | 1 | 2025 | 30 | 0.230 |
Why?
|
| Coloring Agents | 1 | 2005 | 51 | 0.220 |
Why?
|
| Branchioma | 1 | 2005 | 1 | 0.220 |
Why?
|
| Thyroglossal Cyst | 1 | 2005 | 2 | 0.220 |
Why?
|
| Cryotherapy | 1 | 2025 | 16 | 0.220 |
Why?
|
| Eosinophilia | 1 | 2025 | 37 | 0.220 |
Why?
|
| Nose Diseases | 1 | 2005 | 7 | 0.220 |
Why?
|
| Hamartoma | 1 | 2025 | 12 | 0.220 |
Why?
|
| Nervous System Malformations | 1 | 2005 | 12 | 0.220 |
Why?
|
| Hair Follicle | 1 | 2025 | 38 | 0.210 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 1 | 2023 | 4 | 0.200 |
Why?
|
| Oxadiazoles | 1 | 2023 | 8 | 0.200 |
Why?
|
| Neurocutaneous Syndromes | 1 | 2023 | 9 | 0.200 |
Why?
|
| Phototherapy | 1 | 2023 | 35 | 0.190 |
Why?
|
| Castleman Disease | 1 | 2022 | 4 | 0.190 |
Why?
|
| Mucositis | 1 | 2022 | 8 | 0.190 |
Why?
|
| Pemphigus | 1 | 2022 | 14 | 0.190 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2022 | 10 | 0.190 |
Why?
|
| Erythema | 1 | 2022 | 14 | 0.190 |
Why?
|
| Blister | 1 | 2022 | 15 | 0.190 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2022 | 23 | 0.190 |
Why?
|
| Young Adult | 6 | 2025 | 4883 | 0.180 |
Why?
|
| Funnel Chest | 1 | 2021 | 7 | 0.180 |
Why?
|
| Antifungal Agents | 2 | 2017 | 125 | 0.180 |
Why?
|
| Cafe-au-Lait Spots | 2 | 2023 | 7 | 0.170 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 2500 | 0.170 |
Why?
|
| Waxes | 1 | 2020 | 4 | 0.160 |
Why?
|
| Tongue | 1 | 2020 | 18 | 0.160 |
Why?
|
| Emollients | 1 | 2020 | 4 | 0.160 |
Why?
|
| Risk Assessment | 3 | 2019 | 2116 | 0.160 |
Why?
|
| Baths | 1 | 2020 | 7 | 0.160 |
Why?
|
| Eczema | 1 | 2020 | 9 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2022 | 240 | 0.160 |
Why?
|
| Penis | 1 | 2020 | 37 | 0.160 |
Why?
|
| Chronic Pain | 1 | 2022 | 157 | 0.160 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2020 | 12 | 0.160 |
Why?
|
| Dermatitis, Atopic | 1 | 2020 | 31 | 0.160 |
Why?
|
| Corneal Injuries | 1 | 2020 | 1 | 0.160 |
Why?
|
| Severity of Illness Index | 4 | 2025 | 1569 | 0.160 |
Why?
|
| Skin Care | 1 | 2020 | 8 | 0.160 |
Why?
|
| Melanoma | 1 | 2023 | 335 | 0.160 |
Why?
|
| Methadone | 1 | 2021 | 140 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 3 | 2020 | 809 | 0.150 |
Why?
|
| Warts | 1 | 2019 | 7 | 0.150 |
Why?
|
| Detergents | 1 | 2020 | 35 | 0.150 |
Why?
|
| Volunteers | 1 | 2019 | 17 | 0.150 |
Why?
|
| Dermatologists | 1 | 2019 | 12 | 0.150 |
Why?
|
| Keratitis | 1 | 2019 | 19 | 0.150 |
Why?
|
| Child Care | 1 | 2019 | 16 | 0.150 |
Why?
|
| Blindness | 1 | 2020 | 43 | 0.150 |
Why?
|
| Down Syndrome | 1 | 2020 | 45 | 0.150 |
Why?
|
| Cicatrix | 1 | 2020 | 62 | 0.150 |
Why?
|
| Staphylococcal Infections | 1 | 2020 | 131 | 0.150 |
Why?
|
| Empathy | 1 | 2019 | 69 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.140 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 40 | 0.130 |
Why?
|
| Ketoconazole | 1 | 2017 | 11 | 0.130 |
Why?
|
| Fluconazole | 1 | 2017 | 11 | 0.130 |
Why?
|
| Adult | 9 | 2025 | 17579 | 0.130 |
Why?
|
| Forehead | 1 | 2017 | 15 | 0.130 |
Why?
|
| Torso | 1 | 2017 | 21 | 0.130 |
Why?
|
| Pruritus | 1 | 2017 | 32 | 0.130 |
Why?
|
| Patch Tests | 3 | 2021 | 9 | 0.130 |
Why?
|
| Patient Care Team | 1 | 2020 | 338 | 0.130 |
Why?
|
| Burnout, Professional | 1 | 2019 | 145 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 206 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 264 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 220 | 0.130 |
Why?
|
| Skin Pigmentation | 1 | 2016 | 34 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 859 | 0.120 |
Why?
|
| Propylene Glycol | 1 | 2015 | 3 | 0.120 |
Why?
|
| Histamine Antagonists | 1 | 2015 | 8 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 691 | 0.110 |
Why?
|
| Radiography | 1 | 2017 | 559 | 0.110 |
Why?
|
| Excipients | 1 | 2015 | 50 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 737 | 0.110 |
Why?
|
| Inpatients | 1 | 2017 | 322 | 0.110 |
Why?
|
| Neoplasms | 1 | 2005 | 1378 | 0.110 |
Why?
|
| Candidiasis, Cutaneous | 1 | 2014 | 2 | 0.100 |
Why?
|
| Dermatitis, Seborrheic | 1 | 2014 | 6 | 0.100 |
Why?
|
| Infant Welfare | 1 | 2014 | 7 | 0.100 |
Why?
|
| Hydroxides | 2 | 2005 | 5 | 0.100 |
Why?
|
| Potassium Compounds | 2 | 2005 | 4 | 0.100 |
Why?
|
| Pregnancy | 1 | 2021 | 2401 | 0.100 |
Why?
|
| Cheilitis | 1 | 2012 | 5 | 0.090 |
Why?
|
| Clobetasol | 1 | 2012 | 6 | 0.090 |
Why?
|
| Lip | 1 | 2012 | 12 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 169 | 0.080 |
Why?
|
| North America | 2 | 2021 | 114 | 0.080 |
Why?
|
| Canada | 2 | 2020 | 157 | 0.070 |
Why?
|
| Comorbidity | 1 | 2012 | 1122 | 0.070 |
Why?
|
| Darier Disease | 1 | 2008 | 1 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2017 | 1165 | 0.070 |
Why?
|
| Cephalexin | 1 | 2008 | 4 | 0.070 |
Why?
|
| Family Health | 1 | 2008 | 68 | 0.070 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2008 | 50 | 0.070 |
Why?
|
| Neutropenia | 1 | 2008 | 68 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2008 | 104 | 0.060 |
Why?
|
| Dermatofibrosarcoma | 1 | 2025 | 4 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2020 | 888 | 0.060 |
Why?
|
| Mohs Surgery | 1 | 2025 | 54 | 0.060 |
Why?
|
| Incidence | 2 | 2020 | 1433 | 0.060 |
Why?
|
| Atrophy | 1 | 2025 | 89 | 0.050 |
Why?
|
| Mutation | 1 | 2012 | 2675 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2024 | 113 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2025 | 378 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2025 | 256 | 0.050 |
Why?
|
| Mosaicism | 1 | 2023 | 29 | 0.050 |
Why?
|
| Catastrophization | 1 | 2022 | 6 | 0.050 |
Why?
|
| Genotype | 1 | 2025 | 676 | 0.050 |
Why?
|
| Consensus | 1 | 2024 | 175 | 0.050 |
Why?
|
| Tinea | 1 | 2002 | 1 | 0.050 |
Why?
|
| Tinea Pedis | 1 | 2002 | 2 | 0.050 |
Why?
|
| Mycology | 1 | 2002 | 6 | 0.050 |
Why?
|
| Hand Dermatoses | 1 | 2002 | 4 | 0.050 |
Why?
|
| Impetigo | 1 | 2002 | 10 | 0.050 |
Why?
|
| Cellulitis | 1 | 2002 | 16 | 0.050 |
Why?
|
| Melanins | 1 | 2022 | 24 | 0.050 |
Why?
|
| Middle Aged | 3 | 2025 | 18501 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2021 | 233 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 111 | 0.040 |
Why?
|
| Mupirocin | 1 | 2020 | 2 | 0.040 |
Why?
|
| Administration, Ophthalmic | 1 | 2020 | 1 | 0.040 |
Why?
|
| Ophthalmic Solutions | 1 | 2020 | 8 | 0.040 |
Why?
|
| Cosmetics | 1 | 2020 | 17 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 106 | 0.040 |
Why?
|
| Cornea | 1 | 2020 | 35 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2020 | 183 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 133 | 0.030 |
Why?
|
| Parents | 1 | 2022 | 418 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2019 | 252 | 0.030 |
Why?
|
| Age Distribution | 1 | 2019 | 262 | 0.030 |
Why?
|
| Self Care | 1 | 2020 | 218 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 579 | 0.030 |
Why?
|
| Self Report | 1 | 2019 | 395 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 899 | 0.030 |
Why?
|
| Hospitalization | 1 | 2024 | 1404 | 0.030 |
Why?
|
| Dermoscopy | 1 | 2016 | 14 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2016 | 65 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 745 | 0.030 |
Why?
|
| Ophthalmology | 1 | 2016 | 27 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 741 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 104 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 2790 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 1229 | 0.030 |
Why?
|
| Brain | 1 | 2022 | 1672 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 2651 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 2739 | 0.020 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2008 | 13 | 0.020 |
Why?
|
| Candidiasis, Vulvovaginal | 1 | 2008 | 8 | 0.020 |
Why?
|
| Pedigree | 1 | 2008 | 193 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2008 | 371 | 0.020 |
Why?
|